Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, ...

PRNewswire/ -- (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases ...

In this phase3 trial, researchers explored whether a chemotherapy-free strategy was superior to a tyrosine kinase inhibitor plus chemotherapy in Ph-positive ALL.

(p=0.0190). The therapy represents a new non-immune suppressive treatment modality, designed to achieve delivery to the distal colon with a novel liquid to gel delivery system, and a neutral pH. The ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...

If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...

Discover the latest trends in Asia-Australia trade, including rate changes and service updates impacting shipping routes and ...

SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 8.85M Sep 30, 2026 1.24% 132,442,646 SPDR SERIES TRT-State Street SPDR PORT. S&P 500 High Dividend ETF 6.57M Sep 30, 2026 0.92% 98,403,126 ...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical ...

Immuneering is developing Atebimetinib for pancreatic cancer. Early clinical data show a median overall survival of 17.3 ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Monja is in the Miocene belt, between the Cangrejos gold-copper project, acquired by CMOC Group through its acquisition of ...